Bank of America Corporation : In an accumulation phase
Entry price | Target | Stop-loss | Potential |
---|
$30.98 |
$33.9 |
$29.9 |
+9.43% |
---|
Bank of America shares are locked into a trading range. This phase will eventually have to end with a return of a clear trend.
Strengths● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.
● With a P/E ratio at 12.19 for the current year and 10.7 for next year, earnings multiples are highly attractive compared with competitors.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses● The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.